MMS

Name: MMS
Address: 6880 Commerce Boulevard, Canton, MI, 48187, US
Telephone: +17342450310
Price range: Not applicable

MMS is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach.

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet

rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for three consecutive years.

08/28/2026

In our latest blog, we explore how risk-based data management (RBDM) is helping sponsors move beyond traditional data cleaning by prioritizing critical data, strengthening cross-functional collaboration, and enabling more proactive study oversight.

Read the blog to discover practical strategies for implementing a risk-based approach to clinical data management: Risk-Based Data Management: https://hubs.li/Q04vwJhm0

08/27/2026

As MMS celebrates 20 years, we're highlighting the people who have helped shape our journey.

In this video, Amanda Beaster, Senior Director of Regulatory Strategy, reflects on her 14 years at MMS, the shared sense of purpose that drives our teams, and our commitment to continuous improvement in support of sponsors and patients alike. She shares how collaboration, quality, and a focus on making a meaningful impact continue to guide the work we do every day.

Discover what keeps our team inspired at MMS: https://hubs.ly/Q04v096k0

08/25/2026

We're pleased to share that Harry Brown, Associate Director of Business Development, will be attending Nordic Life Science Days, one of the region's premier partnering and networking events for the life science community.

If you're looking to discuss clinical development, regulatory strategy, data science, biometrics, or how MMS helps sponsors navigate complex development programs, connect with Harry during the event.

We look forward to insightful conversations and new opportunities to advance innovation across the life sciences sector.
Book a meeting: https://hubs.ly/Q04v1yk00

08/24/2026

Over the past few months, we've celebrated an incredible milestone across the MMS family: 20 years of innovation, growth, and impact.

From celebrations in the USA, Northern Ireland, and India, colleagues around the world have come together to reflect on our journey, reconnect with teammates, and celebrate the people who have made MMS what it is today. With our South Africa celebration still ahead, we're looking forward to continuing the festivities and marking this milestone with even more members of our global team.

While each event reflects its own local culture and traditions, they all share the same spirit: gratitude for our people, pride in what we've accomplished together, and excitement for what lies ahead.

Thank you to our colleagues, clients, and partners who have been part of our story over the last two decades.

Curious how MMS grew from a vision into a global CRO? Read CEO Uma Sharma's reflections on 20 years of people-first, data-led innovation: https://hubs.li/Q04tYRn20

08/21/2026

The future of psychedelic therapies will be shaped by more than efficacy alone.

In Part 2 of her blog series, MMS CEO Uma Sharma explores the critical questions sponsors must answer around durability, functional unblinding, safety characterization, and scalable care delivery before these therapies can move confidently into real-world practice.

Read the blog: https://hubs.li/Q04tQjCT0

08/20/2026

As innovative therapies move through development, effective risk management becomes increasingly important.

Risk Evaluation and Mitigation Strategies (REMS) can play a critical role in supporting safe use, managing serious risks, and enabling patient access when traditional labeling alone may not be sufficient.

Join former FDA and MMS Senior Medical Director, Somya Dunn and Amanda Beaster, Senior Director of Regulatory Strategy, for a discussion around the regulatory realities sponsors need to understand now: https://hubs.li/Q04tJ5Hy0

08/17/2026

Only three days until our risk-based data management webinar.

As clinical trials become increasingly complex, data management teams must balance quality, efficiency, and oversight. Join Doreen Van Huyssteen, Director of Clinical Data Management, and Lucy Sutton, Vice President of Account Management, to learn how a risk-based approach can help teams prioritize efforts, improve decision-making, and support study success.
Save your seat today: https://hubs.li/Q04tbp7Z0

08/12/2026

FDA efforts to accelerate early clinical development are a welcome step forward, but speed alone doesn't guarantee success. The bigger challenge is ensuring development decisions are based on robust evidence, not assumptions. From patient population estimates and site selection to endpoint strategy and trial design, the choices made before a study begins can shape its entire trajectory.

In this new blog, Uma Sharma, CEO, explores why faster drug development starts with better decision-making, and how real-world evidence, simulation, and connected technologies can help sponsors avoid costly wrong turns before significant time and capital are committed.

Read the blog: https://hubs.li/Q04sLlmW0

08/11/2026

MMS is growing and so is our team!

Across our global team, we’re adding new roles to support the increasing demand for data-driven clinical and regulatory expertise. If you’re looking to be part of a collaborative, science-led CRO, explore our latest opportunities:
· Director, Operational Efficiency & Technology Innovation (US or UK)
· Senior Pharmacovigilance System Architect (US/South Africa)
· Study Design Statistician (US)
· Statistical Programmer II (South Africa)
· Senior Biostatistician (US)
· Senior Medical Writer (US/UK)
· Business and Finance Analyst (India)

Join a team focused on delivering practical, credible solutions that advance clinical development: https://hubs.li/Q04szn_50

08/10/2026

Risk-based data management (RBDM) is helping sponsors focus resources where they matter most by prioritizing critical data, identifying risks earlier, and strengthening oversight throughout the clinical trial lifecycle.

Join our upcoming webinar with Doreen Van Huyssteen,
Director of Clinical Data Management, and Lucy Sutton,
Vice President of Account Management, to learn the key success factors behind effective RBDM implementation and gain practical recommendations to strengthen your data management strategy.

Register today: https://hubs.li/Q04sm_rL0

Address

6880 Commerce Boulevard
Canton, MI
48187

Telephone

+17342450310

Website

http://www.mmsholdings.com/

Alerts

Be the first to know and let us send you an email when MMS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Business in Canton?

MMS